

FACSIMILE

ARNALL GOLDEN & GREGORY, LLP
2800 ONE ATLANTIC CENTER 1201 W. PEACHTREE ST. ATLANTA GEORGIA 30309

TO:

Attention: Examiner G. Kishore, Group 1502

Company: U.S. Patent and Trademark Office

Company Telephone: 703 308 2440

FAX Number: 703 305 5408

Direct Number: _____

THE INFORMATION CONTAINED IN THIS TELECOPIER MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT DESIGNATED ABOVE. This information may be within the attorney-client privilege and/or constitute a confidence or secret under the applicable legal and ethical rules. As such, it may be both privileged and confidential.

If the reader of this message is not the intended recipient or a duly authorized agent responsible for delivering it to the intended recipient, you are hereby notified that this document has been received in error. Furthermore, any review, dissemination, distribution or copying of this message is strictly prohibited.

If you have received this communication in error, please notify us immediately by telephone and return the original message and any copies to us by mail. We will reimburse you for any reasonable direct or indirect costs you incur connected with the requested telephone call and mailing. We appreciate your courtesy.

RECEIVED
05/14/97
JPD

FROM: Patrea L. Pabst

Direct Number: (404) 873-8794

Total Pages Including This Cover Sheet: 7 Date: May 14, 1997

Matter: WC103

File Number: 20260/10

MESSAGE: _____

If you do not receive the correct number of pages or are disconnected, please call (404) 873-8500 as soon as possible and ask for: (check one)

Communications Center or _____

27/7 (02)

AMENDMENT UNDER 37 C.F.R. §1.116
EXPEDITED PROSECUTION
ART UNIT 1502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd
5-21-97

Applicant: Lisbeth Illum

Serial No.: 08/359,937

Group Art Unit: 1502

RECEIVED

MAY 14 1997

Filed: December 20, 1994

Examiner: G. Kishore

GROUP 1500

For: SMALL PARTICLE COMPOSITIONS FOR
INTRANASAL DRUG DELIVERYAssistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

Responsive to the Office Action mailed April 29, 1997, and the very helpful telephone interview with the Examiner on May 13, 1997, please amend the application as follows.

In the Claims

Please cancel claims 1-12, 15 and 16.

13. (amended) [A] The method of claim 17 for delivering a drug to the nasal mucosa, comprising introducing a gas stream containing [a] the composition [according to Claim 1] into the nose.

33